R-Tech initiates hypotrichosis drug study
The placebo-controlled, double-blind study evaluates the safety, tolerability, and pharmacokinetics of RK-023 in healthy adult male and female volunteers, who will apply the study drug to the eyelid
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Boehringer Ingelheim will carry out the technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan. Elan will guide the discovery science,
POTELLIGENT CHOK1SV is a new host cell line for manufacturing recombinant antibodies. It combines the power of BioWa’s engineered glycosylation POTELLIGENT Technology with the advantages of Lonza’s proprietary